Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast CancerMaurizio Scaltriti, José Baselga|JNCI Journal of the National Cancer Institute|2007Cited by 876
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionYasir H. Ibrahim, José Baselga, Olga Rodríguez et al.|Cancer Discovery|2012Cited by 622
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα InhibitionPau Castel, Maurizio Scaltriti|Cancer Cell|2016Cited by 228
Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast CancerJessica J. Tao, Maurizio Scaltriti, Pau Castel et al.|Science Signaling|2014Cited by 166
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast CancerMaurizio Scaltriti, José Baselga|Molecular Cancer Therapeutics|2011Cited by 52